<DOC>
	<DOCNO>NCT03020095</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability Ravidasvir ( ASC16 ) combination Ritonavir-boosted Danoprevir ( ASC08 ) Ribavirin treatment-naive no-cirrhotic Taiwanese patient chronic hepatitis C genotype1 .</brief_summary>
	<brief_title>Efficacy Safety Ravidasvir + Danoprevir/r 12-week Oral Therapy Treatment-Naive Non Cirrhotic G1 CHC Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Willing able provide write informed consent Chronic HCV infection ( ≥6 month ) , HCV RNA ≥ 1 × 104 IU/mL Never receive priortreatment HCV interferon , RBV , directacting hosttargeting antiviral HCV Chronic liver disease consistent CHC infection without cirrhosis determine biopsy obtain within past calendar 36 month use one liver biopsy method protocol ( noncirrhosis define : Metavir score ˂ 4 ) , determine Fibroscan define : ˂ 14.6 kPa . Patients obtain liver biopsy Fibroscan last 3 year study related Fibroscan perform order confirm diagnosis . Liver biopsy perform investigator 's judgement All male patient female partner childbearing potential must use two reliable form effective contraception ( combine ) treatment 6 month follow last dose ribavirin Others specify detailed protocol . Pregnant lactating woman . History presence decompensated liver disease ( history ascites , hepatic encephalopathy , HCC , bleed esophageal varix ) Presence history nonhepatitis C chronic liver disease , include limited , autoimmune hepatitis , α1antitrypsin deficiency , C282Y homozygous hemochromatosis , Wilson 's disease , drug toxininduced liver disease , alcoholrelated liver disease , primary biliary cirrhosis , sclerosing cholangitis , porphyria cutanea tarda cause liver pathology require phlebotomy Positive hepatitis B surface antigen HIV antibody screen History presence liver cirrhosis History severe psychiatric disease , include psychosis and/or depression , able participate able give write informed consent comply study restriction History active malignancy within last 5 year , exception localize situ carcinoma ( e.g. , basal squamous cell carcinoma skin ) History severe cardiac disease ( e.g. , New York Heart Association Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmia 's require ongoing treatment , unstable angina unstable , uncontrolled significant cardiovascular disease within 6 month ) . Patients stable coronary artery disease ( e.g. , 6 month bypass surgery , angioplasty without stent placement , etc . ) confirm cardiologist permit . In addition , patient document presumed unstable coronary artery disease , cardiovascular disease , cerebrovascular disease enrol . Any patient increase risk anemia ( e.g. , thalassemia , sickle cell anemia , spherocytosis ) anemia would medically problematic History preexist renal disease , patient history nephrolithiasis allow Others specify detailed protocol .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ravidasvir</keyword>
	<keyword>HCV GT1</keyword>
	<keyword>SVR12</keyword>
	<keyword>Danoprevir/r</keyword>
</DOC>